Related Experiment Videos

[In vitro antibacterial activity of eight third generation cephalosporins (author's transl)]

Pathologie-Biologie
|June 1, 1982
PubMed

Insights

This study evaluated eight third-generation cephalosporins, finding cefotaxime, moxalactam, cefmenoxime, ceftriaxone, and ceftazidime most effective against resistant Enterobacteriaceae. Ceftazidime excelled against Pseudomonas aeruginosa, and moxalactam against Bacteroides.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Third-generation cephalosporins represent a critical class of antibiotics.
  • Emergence of antibiotic resistance necessitates evaluation of newer agents.
  • Enterobacteriaceae and Pseudomonas aeruginosa are significant pathogens.

Purpose of the Study:

  • To assess the in vitro antibacterial activity of eight third-generation cephalosporins.
  • To identify superior agents against cefalothin-resistant Enterobacteriaceae.
  • To compare efficacy against specific challenging pathogens like Pseudomonas aeruginosa and Bacteroides.

Main Methods:

  • In vitro susceptibility testing of eight third-generation cephalosporins.
  • Evaluation of antibacterial spectrum and potency.
  • Comparative analysis of efficacy against various bacterial groups, including Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides.

Main Results:

  • Five cephalosporins (cefotaxime, moxalactam, cefmenoxime, ceftriaxone, ceftazidime) demonstrated superior activity against cefalothin-resistant Enterobacteriaceae.
  • Ceftazidime exhibited the strongest activity against Pseudomonas aeruginosa.
  • Moxalactam was most effective against the Bacteroides group.
  • No significant superiority over older agents was observed against other bacterial groups.

Conclusions:

  • Certain third-generation cephalosporins offer significant advantages against resistant Enterobacteriaceae.
  • Ceftazidime and moxalactam show specific strengths against key pathogens.
  • These findings guide the selection of appropriate cephalosporins for treating infections caused by resistant bacteria.

Related Concept Videos